Ariad Pharmaceuticals, Inc.
NASDAQ: ARIA
$23.99
+$0.00 (+0.0%)
Closing price February 17, 2017
The top analyst upgrades, downgrades and initiations on Tuesday include American Express, Goldman Sachs, Illumina, PayPal, Trivago and Williams Companies.
6 years ago
Last Updated: 3 years ago
As the second week of the New Year is now underway, a few biotech companies made sizable runs to kick off the week.
6 years ago
Last Updated: 3 years ago
24/7 Wall St. has identified several immediate winners from a Donald Trump presidency. These are all surging higher.
6 years ago
Last Updated: 3 years ago
Ariad Pharmaceuticals said it had a loss in the most recent quarter. However, incredibly positive growth for its flagship drug pulled this company through.
6 years ago
Last Updated: 3 years ago
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK Partners and Sunrun.
6 years ago
Last Updated: 3 years ago
Shares of Ariad Pharmaceuticals saw a modest gain early Monday after the company announced a recent FDA decision.
6 years ago
Last Updated: 3 years ago
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Ariad Pharmaceuticals, AT&T, Chesapeake Energy, Hain Celestial, Nike and Visa.
6 years ago
Last Updated: 3 years ago
Ariad Pharmaceuticals shares were down handily on Monday after JPMorgan downgraded the stock. Also Senator Sanders recently asked about the pricing of its blood cancer drug Iclusig.
6 years ago
Last Updated: 3 years ago
The top analyst upgrades, downgrades and initiations seen on Monday morning include Ariad Pharmaceuticals, Comcast, ConEd, Electronic Arts, Kinder Morgan, 3M and Time Warner.
6 years ago
Last Updated: 3 years ago
A new research report from Jefferies notes that when price momentum has been as bad as it has been recently, it tends to rebound in a big way.
6 years ago
Last Updated: 3 years ago
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.
6 years ago
Last Updated: 3 years ago
The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from June 3 to June 7 in Chicago.
7 years ago
Last Updated: 3 years ago
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
7 years ago
Last Updated: 3 years ago
Source: ThinkstockThe solid performance of the healthcare sector over the past year has been enhanced by mergers and acquisitions, licensing, and other forms of deals in the sector. This most recent...
8 years ago
Last Updated: 8 years ago
In a new report, Stifel sees two biotech stocks with near-term catalysts that could make takeover candidates soon.
8 years ago
Last Updated: 8 years ago